FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Market Closed - Börse Stuttgart 05:38:46 03/07/2024 pm IST | ||
| 276.8 EUR | -3.95% |
|
| Current month | +3.14% | ||
| 1 month | +177.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 276.8 | -3.95% |
| 02/24/02 | 288.2 | -13.93% |
| 01/24/01 | 334.8 | +24.76% |
| 28/24/28 | 268.4 | +8.26% |
| 27/24/27 | 247.9 | -10.43% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 05:38 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MB1CZN |
| ISIN | DE000MB1CZN6 |
| Date issued | 12/12/2022 |
| Strike | 675.1 kr |
| Maturity | Unlimited |
| Parity | 0.11 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 334.8 € |
|---|---|
| Lowest since issue | 5.45 € |
| Spread | 10.05 € |
| Spread % | 3.63% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
890
DKK
Average target price
918
DKK
Spread / Average Target
+3.15%
- Stock Market
- Certificates
- Certificat
